Search results
Results from the WOW.Com Content Network
Injections of hyaluronidase around the area can be used to speed the dispersal of the fluid/drug. [51] Infiltration is one of the most common adverse effects of IV therapy [52] and is usually not serious unless the infiltrated fluid is a medication damaging to the surrounding tissue, most commonly a vesicant or chemotherapeutic agent.
Hyaluronidase can be injected to dissolve hyaluronic acid type dermal fillers and is the best treatment option for those looking at dissolving lip filler or dealing with related complications. [ 17 ] Purified and recombinant hyaluronidases
Clinical trial number NCT05232825 for "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)" at ClinicalTrials.gov
Hyaluronic acid fillers can be quickly dissolved with the injection of an enzyme, hyaluronidase, which "breaks down hyaluronic acid into smaller particles so that your body can absorb it quickly ...
Bovhyaluronidase azoximer, sold under the brand name Longidaze, is a conjugate of proteolytic enzyme hyaluronidase with high- molecular weight copolymer that forms a component of combination therapy regimens for treatment and prevention of diseases associated with connective tissue hyperplasia. [1]
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. [ 1 ] [ 2 ] Nivolumab/hyaluronidase contains nivolumab , a programmed death receptor-1 (PD-1)-blocking monoclonal antibody ; and hyaluronidase , an endoglycosidase . [ 1 ]
The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...